Other ways to search: Events Calendar | UTHSC

Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting


Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET – 1:30pm EST.

The event will focus on the company’s US product candidate, HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system), a percutaneous hepatic perfusion (PHP) system. In the United States HEPZATO is an investigational drug/device combination product. In Europe, the product is a stand-alone medical device approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Among speakers:

Evan S. Glazer, MD, PhD, FACS
Assistant Professor of Surgery, College of Medicine and Principal Investigator, Center for Cancer Research, The University of Tennessee Health Science Center, Memphis, TN


Top Publishers